此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项关于Buntanetap在帕金森病患者中的研究

2026年10月28日 更新者:Annovis Bio Inc.

一项开放标签临床试验:研究 Buntanetap 治疗帕金森病参与者的长期安全性

This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days.

研究概览

详细说明

This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days. MMSE, MoCA, C-SSRS, and MDS-UPDRS will be assessed by clinicians who have successfully completed the requisite certifications/trainings for each assessment. Each participant shall be assessed by the same clinician throughout the study. Cohort 1 participants will stop standard of care Parkinson's medications 12h before baseline and annual clinical visits to ensure clinical OFF-state during visit. Cohort 2 participants will stop standard of care Parkinson's medications 12h before all clinic visits. The night before the baseline and annual clinic visits (or early termination visit), Cohort 2 participants will return DBS settings to their initial baseline settings.

研究类型

介入性

注册 (估计的)

500

阶段

  • 阶段2
  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Alabama
      • Birmingham、Alabama、美国、35233
        • 招聘中
        • University of Alabama at Birmingham
        • 接触:
        • 首席研究员:
          • Natividad Stover, M.D.
    • Arizona
      • Sun City、Arizona、美国、85351
        • 招聘中
        • Banner Sun Health Research Institute - Cleo Roberts Center for Clinical Research
        • 首席研究员:
          • Sara Dhanani, M.D.
        • 接触:
    • California
      • Fountain Valley、California、美国、92708
        • 招聘中
        • Parkinson's & Movement Disorder Institute (PMDI) - Orange County Office
        • 首席研究员:
          • Daniel Truong, M.D.
        • 接触:
          • Evan Moreno-Davis
          • 电话号码:714-378-5074
          • 邮箱:evan@pmdi.org
    • Colorado
      • Englewood、Colorado、美国、80113
        • 招聘中
        • Cenexel Rocky Mountain Clinical Research
        • 接触:
        • 首席研究员:
          • Meagen Salinas, M.D.
    • Connecticut
      • Stamford、Connecticut、美国、06824
        • 招聘中
        • New England Institute for Clinical Research (Ki Health Partners)
        • 接触:
        • 首席研究员:
          • Peter McAllister, M.D.
    • Florida
      • Aventura、Florida、美国、33180
        • 招聘中
        • First Choice Neurology - Aventura Neurologic Associates
        • 首席研究员:
          • Jonathan Cross, M.D.
        • 接触:
      • Daytona Beach、Florida、美国、32117
        • 招聘中
        • Arrow Clinical Trials
        • 接触:
        • 首席研究员:
          • David Billmeier, M.D.
      • DeLand、Florida、美国、32720
        • 招聘中
        • Accel Clinical Sites-Georgia LLC dba Accel Research Sites-Lake Oconee CRU
        • 首席研究员:
          • Bruce Rankin, D.O.
        • 接触:
      • Miami、Florida、美国、33172
      • Miami、Florida、美国、33015
        • 尚未招聘
        • Ezy Medical Research Co.
        • 接触:
      • Ocala、Florida、美国、34470
        • 招聘中
        • Renstar Medical Research
        • 首席研究员:
          • Annette Nieves, M.D.
        • 接触:
      • Tampa、Florida、美国、33613
        • 招聘中
        • University of South Florida (USF) - University of South Florida College of Medicine - Parkinson's Di
        • 接触:
        • 首席研究员:
          • Robert Hauser, M.D., MBA
      • Winter Park、Florida、美国、32789
    • Georgia
      • Decatur、Georgia、美国、30030
        • 招聘中
        • iResearch Atlanta
        • 接触:
        • 首席研究员:
          • Kimball Johnson, M.D.
    • Indiana
      • Indianapolis、Indiana、美国、46256
        • 招聘中
        • Josephson Wallack Munshower Neurology, P.C.
        • 首席研究员:
          • Kristi George, M.D.
        • 接触:
    • Kansas
      • Kansas City、Kansas、美国、66160
        • 招聘中
        • University of Kansas Medical Center (KUMC) - School of Medicine - Parkinson's Disease and Movement D
        • 接触:
        • 首席研究员:
          • Rajesh Pahwa, M.D.
    • Michigan
      • Farmington Hills、Michigan、美国、48334
        • 招聘中
        • Quest Research Institute
        • 首席研究员:
          • Aaron Ellenbogen, D.O.
        • 接触:
    • New York
      • New York、New York、美国、10019
        • 招聘中
        • Mount Sinai Hospital
        • 首席研究员:
          • Joohi Jimenez-Shahed, M.D.
        • 接触:
    • North Carolina
      • Durham、North Carolina、美国、27710
        • 招聘中
        • Duke Department of Neurosurgery
        • 首席研究员:
          • Kyle Mitchell, M.D.
        • 接触:
    • Ohio
      • Columbus、Ohio、美国、43210
        • 招聘中
        • The Ohio State University Wexner Medical Center
        • 首席研究员:
          • Zachary Jordan, M.D.
        • 接触:
    • Oklahoma
      • Tulsa、Oklahoma、美国、74136
        • 招聘中
        • The Movement Disorder Clinic of Oklahoma
        • 接触:
        • 首席研究员:
          • Kevin Klos, M.D.
    • Pennsylvania
      • Willow Grove、Pennsylvania、美国、19090
        • 招聘中
        • Abington Neurology
        • 首席研究员:
          • David Weisman, M.D.
        • 接触:
    • South Carolina
      • Charleston、South Carolina、美国、29401
        • 招聘中
        • Medical University of South Carolina (MUSC) - The Murray Center for Research on Parkinson's Disease
        • 接触:
        • 首席研究员:
          • Vanessa Hinson, M.D., PhD
    • Tennessee
      • Cordova、Tennessee、美国、38018
        • 招聘中
        • Neurology Clinic, P.C.
        • 接触:
        • 首席研究员:
          • Kendrick Henderson, M.D.
      • Memphis、Tennessee、美国、38157
        • 招聘中
        • Veracity Neuroscience LLC
        • 接触:
        • 首席研究员:
          • Mark LeDoux, M.D., PhD
    • Texas
      • Round Rock、Texas、美国、78681
        • 招聘中
        • Central Texas Neurology
        • 接触:
        • 首席研究员:
          • Elizabeth Peckham, M.D.
    • Virginia
      • Charlottesville、Virginia、美国、22903
        • 招聘中
        • University of Virginia Health System (UVAHS) - Adult Neurology Clinic
        • 首席研究员:
          • Binit Shah, M.D.
        • 接触:
    • Washington
      • Spokane、Washington、美国、99202
        • 招聘中
        • Inland Northwest Research
        • 首席研究员:
          • Jason Aldred, M.D.
        • 接触:
    • Wisconsin
      • Milwaukee、Wisconsin、美国、53226
        • 招聘中
        • Medical College of Wisconsin
        • 接触:
        • 首席研究员:
          • Karen Blindauer, M.D.

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

40年 至 85年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Diagnosis of idiopathic PD according to MDS Clinical Diagnostic Criteria for Parkinson's Disease (Postuma et al., 2015) and

    a. Cohort 1: Participated in a prior PD clinical trial with buntanetap. i. A legally authorized representative is required for any participant whose MMSE <21 at screening.

    b. Cohort 2: Has been receiving DBS treatment in either 1) the subthalamic nucleus or 2) the globus pallidus internus for at least 12 months after a successful DBS surgery that achieved the goal.

    i. Female or male adults aged 40 to 85 years. ii. H&Y stage 1-3 in ON state. iii. MMSE 21-30 at screening and baseline.

  2. Have a support person who will accompany the participant on study visits at designated times.

  3. Female participants of childbearing potential* must have a negative urine pregnancy test at screening, must be non-lactating, and must agree to use a highly effective method of contraception (i.e., a method resulting in a failure rate of less than 1% per year when used consistently and correctly) during the trial and for one month after the last dose of trial treatment, such as:

    1. Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,

    2. Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,

    3. Intrauterine device (IUD),

    4. Intrauterine hormone-releasing system (IUS),

    5. Bilateral tubal occlusion,

    6. Vasectomized partner (a vasectomized partner is a highly effective contraception method provided that the partner is the sole male sexual partner of the participant, and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used),

    7. Sexual abstinence (sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant).

      • Non-childbearing potential includes surgically sterilized or postmenopausal with no menstrual bleeding for at least one year prior to study start.

    Protocol ANVS-25002 Ver. 2.1; 09-23-2025 Confidential Page 30 of 54

  4. Male participants must be sterile or sexually inactive or agree not to father a child during the study and one month after the last dose of study medication and must agree to use a barrier method for contraception. Female partners of male participants must adopt a highly effective method of contraception with a failure rate of less than 1% per year when used consistently and correctly such as:

    1. Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,
    2. Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,
    3. IUD,
    4. IUS,
    5. Bilateral tubal occlusion.
  5. No evidence of current suicidal ideation or previous suicide attempt in the past month as evaluated in the C-SSRS.

  6. Stability of permitted medications for at least 4 weeks prior to screening. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

    1. Standard of care anti-parkinsonian medication,
    2. Cholinesterase inhibitors and/or memantine medication,
    3. Anticonvulsant medications used for epilepsy or mood stabilization, or neuropathic pain indications, and have not had a breakthrough seizure 3 years prior to screening,
    4. Mood-stabilizing psychotropic agents including, but not limited to, lithium,
  7. Adequate visual and hearing ability (physical ability to perform all the study assessments).

  8. Good general health with no disease expected to interfere with the study.

Exclusion Criteria:

  1. Cohort 1 only: Is currently receiving DBS treatment. (Participant may enroll in Cohort 2 if they meet the corresponding inclusion/exclusion criteria).

  2. A history of psychiatric disorder such as schizophrenia, bipolar disorder, or major depression according to the criteria of the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM), unless their symptoms have been mild, and they are stable on treatment or no longer need treatment. Mild depression or history of depression that is stable on treatment with selective serotonin reuptake inhibitors (SSRI) or serotonin and norepinephrine reuptake inhibitors (SNRI) medication at a stable dose is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

  3. A history of seizure disorder. If stable on medication, it is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

  4. A history or current evidence of long QT syndrome, Fridericia's formula corrected QT (QTcF) interval ≥ 450 ms for men and ≥ 460 ms for women, or torsades de pointes.

  5. Bradycardia (<50 bpm) or tachycardia (>100 bpm) on the ECG at screening and deemed medically significant by the PI.

    Protocol ANVS-25002 Ver. 2.1; 09-23-2025 Confidential Page 31 of 54

  6. Uncontrolled Type-1 or Type-2 diabetes. A participant with hemoglobin subunit alpha 1c (HbA1c) levels up to 7.5% can be enrolled if the investigator believes the participant's diabetes is under control.

  7. Clinically significant renal (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] <50 mL/min/BSA [body surface area]) or hepatic impairment (Alkaline phosphatase [ALP] > 2.0X the upper limit of normal [ULN] and/or total bilirubin > 2.0X ULN).

  8. Any clinically significant abnormal laboratory values. Participants with liver function tests (aspartate aminotransferase [AST] or alanine aminotransferase [ALT]) greater than twice ULN will be excluded.

  9. Is at imminent risk of self-harm, based on clinical interview and responses on the C-SSRS, or of harm to others in the opinion of the investigators. Participants must be excluded if they report suicidal ideation with intent, with or without a plan or method (e.g., positive response to Items 4 or 5 in assessment of suicidal ideation on C-SSRS) in the past 2 months, or suicidal behavior in the past 6 months.

  10. Cancer or has had a malignant tumor within the past year, except participants who underwent potentially curative therapy with no evidence of recurrence (participants with stable untreated cancer are not excluded).

  11. Alcohol / Substance use disorder, moderate to severe, in the last 5 years according to the most current version of the DSM.

  12. Participation in another clinical trial with an investigational agent and have taken at least one dose of study medication, unless unblinded on placebo, within 4 weeks prior to the start of screening, or five half-lives of the investigational drug, whichever is greater. The end of a previous investigational trial is the date the last dose of an investigational agent was taken.

  13. A learning disability or developmental delay.

  14. Participants whom the site PI deems to be otherwise ineligible.

  15. A known allergy to the investigational drug or any of its components.

    Inactive ingredients of the investigational medicinal product:

    • Silicified microcrystalline cellulose
    • Dibasic calcium phosphate dihydrate
    • Mannitol
    • Stearic acid
    • Hypromellose (capsule shells structure)
    • Titanium dioxide (opacifier of the capsule shells)
  16. Is currently pregnant, breast-feeding, and/or lactating.

  17. Uncontrolled hypertension (systolic >160mmHg and/or diastolic >95mmHg) or hypotension (systolic <90mmHg and/or diastolic <60 mmHg) and deemed medically significant by the PI.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Cohort 1 - buntanetap

Cohort 1 will enroll via invitation only for PD participants who have previously participated in bun

buntanetap capsules 30 mg by mouth daily

实验性的:Cohort 2 - buntanetap

Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment.

buntanetap capsules 30 mg by mouth daily

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Safety of buntanetap
大体时间:36-months of treatment

Safety assessments of participants with PD receiving treatment with buntanetap

36-months of treatment
Adverse Events (AE)
大体时间:36-months of treatment

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention

36-months of treatment
Treatment Emergent Adverse Events (TEAE)
大体时间:36-months of treatment

TEAE is an event that emerges during treatment, having been absent pretreatment, or worsens relative to the pretreatment state

36-months of treatment
Serious Adverse Events (SAE)
大体时间:36-months of treatment

SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization, or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a birth defect or congenital anomaly

36-months of treatment

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Laurie Sanders, Ph.D.、Duke Clinical Research Institute

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年1月9日

初级完成 (估计的)

2029年9月1日

研究完成 (估计的)

2029年11月1日

研究注册日期

首次提交

2025年11月26日

首先提交符合 QC 标准的

2025年12月9日

首次发布 (实际的)

2025年12月16日

研究记录更新

最后更新发布 (实际的)

2026年10月30日

上次提交的符合 QC 标准的更新

2026年10月28日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅